08Apr/19
The Latest Development of PARP Inhibitors, Bispecific Antibodies and other Hot Spots
In 2018, Loxo Oncology’s “unlimited cancer” targeted therapy Vitrakvi was approved by FDA, becoming the first targeted therapy for patients with NTRK gene fusion variant solid tumors. Loxo, on the other hand,Read More…